$ANAB
ANAPTYSBIO, INC Stock $anab

$anab Overview Financials Valuation SEC Filings Company Website

2020 Q1 Form 10-K Financial Statement

#000137005320000009 Filed on March 02, 2020

Income Statement

Concept	2020 Q1	2019 Q4	2019 Q3
Revenue	$15.00M	$3.000M	$0.00
YoY Change			-100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$4.290M	$3.830M	$3.810M
YoY Change	3.62%	2.41%	-4.75%
% of Gross Profit
Research & Development	$20.97M	$21.43M	$29.93M
YoY Change	1.63%	34.61%	67.37%
% of Gross Profit
Depreciation & Amortization	$140.0K	$140.0K	$130.0K
YoY Change	21.74%	27.27%	44.44%
% of Gross Profit
Operating Expenses	$25.25M	$25.26M	$33.75M
YoY Change	1.94%	28.48%	54.18%
Operating Profit	-$10.25M	-$22.26M	-$33.75M
YoY Change	-58.61%	13.2%	99.83%
Interest Expense	$0.00	$2.080M	$240.0K
YoY Change	-100.0%	-15.79%	-40.0%
% of Operating Profit
Other Income/Expense, Net	$1.991M	-$110.0K	$2.661M
YoY Change	-25.57%	-1200.0%	186.44%
Pretax Income	-$8.262M	-$20.29M	-$31.08M
YoY Change	-62.61%	18.03%	94.79%
Income Tax	$0.00	-$20.00K	-$51.00K
% Of Pretax Income
Net Earnings	-$8.262M	-$20.26M	-$31.03M
YoY Change	-62.58%	19.25%	94.47%
Net Earnings / Revenue	-55.08%	-675.33%
Basic Earnings Per Share		-$0.75	-$1.15
Diluted Earnings Per Share	-$303.0K	-$0.75	-$1.15
COMMON SHARES
Basic Shares Outstanding	27.27M shares	27.13M shares	27.05M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2020 Q1	2019 Q4	2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$362.5M	$374.2M	$421.0M
YoY Change	-12.79%	-12.38%	-14.74%
Cash & Equivalents	$165.3M	$171.0M	$182.9M
Short-Term Investments	$197.2M	$203.2M	$238.1M
Other Short-Term Assets	$3.600M	$3.500M	$3.600M
YoY Change	-40.98%	-50.0%	-10.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$371.1M	$377.7M	$424.6M
YoY Change	-12.06%	-13.01%	-15.59%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.610M	$1.618M	$1.695M
YoY Change	1.64%	11.97%	26.12%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$50.20M	$54.30M	$23.40M
YoY Change	-26.82%	-25.72%	25.81%
Other Assets	$1.293M	$1.481M	$1.735M
YoY Change	-38.1%	900.68%	2096.2%
Total Long-Term Assets	$53.18M	$57.46M	$26.91M
YoY Change	-26.43%	-23.16%	33.88%
TOTAL ASSETS
Total Short-Term Assets	$371.1M	$377.7M	$424.6M
Total Long-Term Assets	$53.18M	$57.46M	$26.91M
Total Assets	$424.2M	$435.2M	$451.5M
YoY Change	-14.16%	-14.5%	-13.69%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$8.571M	$16.24M	$10.52M
YoY Change	-5.52%	198.31%	70.26%
Accrued Expenses	$13.78M	$11.05M	$15.29M
YoY Change	64.06%	26.15%	113.94%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$1.400M	$3.100M
YoY Change	-100.0%	-81.58%	-58.67%
Total Short-Term Liabilities	$23.25M	$29.54M	$29.73M
YoY Change	-6.08%	35.26%	42.43%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Other Long-Term Liabilities	$419.0K	$654.0K	$883.0K
YoY Change	-68.19%	-17.84%	341.5%
Total Long-Term Liabilities	$419.0K	$654.0K	$883.0K
YoY Change	-68.19%	-17.84%	-66.04%
TOTAL LIABILITIES
Total Short-Term Liabilities	$23.25M	$29.54M	$29.73M
Total Long-Term Liabilities	$419.0K	$654.0K	$883.0K
Total Liabilities	$23.67M	$30.19M	$30.61M
YoY Change	-9.21%	33.39%	30.82%
SHAREHOLDERS EQUITY
Retained Earnings	-$252.3M	-$244.0M	-$223.8M
YoY Change	49.49%	66.35%	72.53%
Common Stock	$27.00K	$27.00K	$27.00K
YoY Change	0.0%	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$400.6M	$405.0M	$420.9M
YoY Change
Total Liabilities & Shareholders Equity	$424.2M	$435.2M	$451.5M
YoY Change	-14.16%	-14.5%	-13.69%

Cashflow Statement

Concept	2020 Q1	2019 Q4	2019 Q3
OPERATING ACTIVITIES
Net Income	-$8.262M	-$20.26M	-$31.03M
YoY Change	-62.58%	19.25%	94.47%
Depreciation, Depletion And Amortization	$140.0K	$140.0K	$130.0K
YoY Change	21.74%	27.27%	44.44%
Cash From Operating Activities	-$15.11M	-$15.81M	-$22.09M
YoY Change	-6.13%	28.64%	48.65%
INVESTING ACTIVITIES
Capital Expenditures	$87.00K	-$110.0K	-$280.0K
YoY Change	-51.67%	-45.0%	-12.5%
Acquisitions
YoY Change
Other Investing Activities	$10.84M	$4.140M	$60.15M
YoY Change	10.16%	-102.49%	141.18%
Cash From Investing Activities	$10.75M	$4.030M	$59.87M
YoY Change	11.33%	-102.43%	143.18%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$1.339M	-110.0K	-1.420M
YoY Change	2.92%	-92.03%	-100.63%
NET CHANGE
Cash From Operating Activities	-$15.11M	-15.81M	-22.09M
Cash From Investing Activities	$10.75M	4.030M	59.87M
Cash From Financing Activities	-$1.339M	-110.0K	-1.420M
Net Change In Cash	-$5.700M	-11.89M	36.36M
YoY Change	-26.39%	-93.39%	-84.62%
FREE CASH FLOW
Cash From Operating Activities	-$15.11M	-$15.81M	-$22.09M
Capital Expenditures	$87.00K	-$110.0K	-$280.0K
Free Cash Flow	-$15.20M	-$15.70M	-$21.81M
YoY Change	-6.63%	29.86%	50.0%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2019Q4	anab	Other Commitments Due After Year One OtherCommitmentsDueAfterYearOne	200000	USD
CY2019	dei	Amendment Flag AmendmentFlag	false
CY2019	dei	Entity Address City Or Town EntityAddressCityOrTown	San Diego
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2019	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2018Q4	us-gaap	Restricted Cash RestrictedCash	60000	USD
CY2017	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	0	USD
CY2018	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	0	USD
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2018Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2019	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2019	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
CY2019	dei	Entity Central Index Key EntityCentralIndexKey	0001370053
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	26922000	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	27255000	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	26922000	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	27255082	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	27255000	shares
CY2017	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	0	USD
CY2017	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0	USD
CY2018	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	55000	USD
CY2019	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	153000	USD
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2018	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	USD
CY2019	dei	Document Type DocumentType	10-K
CY2019	dei	Document Annual Report DocumentAnnualReport	true
CY2019	dei	Document Period End Date DocumentPeriodEndDate	2019-12-31
CY2019	dei	Document Transition Report DocumentTransitionReport	false
CY2019	dei	Entity File Number EntityFileNumber	001-37985
CY2019	dei	Entity Registrant Name EntityRegistrantName	ANAPTYSBIO, INC.
CY2019	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2019	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-3828755
CY2019	dei	Entity Address Address Line1 EntityAddressAddressLine1	10421 Pacific Center Court
CY2019	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 200
CY2019	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2019	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-97336000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-61656000	USD
CY2019	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92121
CY2019	dei	City Area Code CityAreaCode	858
CY2019	dei	Local Phone Number LocalPhoneNumber	362-6295
CY2019	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value
CY2019	dei	Trading Symbol TradingSymbol	ANAB
CY2019	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2019	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2019	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2019	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2019	dei	Entity Small Business EntitySmallBusiness	false
CY2019	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2019	dei	Entity Shell Company EntityShellCompany	false
CY2019Q2	dei	Entity Public Float EntityPublicFloat	1391103537	USD
CY2020Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	27265262	shares
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	8000000	USD
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5000000	USD
CY2017	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	10000000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-107432000	USD
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	-66722000	USD
CY2017	us-gaap	Operating Income Loss OperatingIncomeLoss	-28781000	USD
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-30070000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-97336000	USD
CY2018	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-61656000	USD
CY2017	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-30070000	USD
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.60
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.50
CY2017	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.52
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	171017000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	113596000	USD
CY2019Q4	anab	Research And Development Tax Incentive Credit Receivable Current ResearchAndDevelopmentTaxIncentiveCreditReceivableCurrent	0	USD
CY2018Q4	anab	Research And Development Tax Incentive Credit Receivable Current ResearchAndDevelopmentTaxIncentiveCreditReceivableCurrent	174000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	203210000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	313486000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3506000	USD
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6960000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1618000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1445000	USD
CY2018Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	633251000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	27000	USD
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	27000	USD
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	648669000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	377733000	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	434216000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	54305000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	73128000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1481000	USD
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	148000	USD
CY2019Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	60000	USD
CY2018Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	60000	USD
CY2019Q4	us-gaap	Assets Assets	435197000	USD
CY2018Q4	us-gaap	Assets Assets	508997000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	16237000	USD
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5443000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	11052000	USD
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8761000	USD
CY2019Q4	us-gaap	Notes Payable Current NotesPayableCurrent	1375000	USD
CY2018Q4	us-gaap	Notes Payable Current NotesPayableCurrent	7574000	USD
CY2019Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	871000	USD
CY2018Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	58000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	29535000	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	21836000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	654000	USD
CY2018Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	796000	USD
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	338000	USD
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-223000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-244026000	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-146690000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	405008000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	486365000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	435197000	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	508997000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	8000000	USD
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5000000	USD
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	16094000	USD
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-30070000	USD
CY2017	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	10000000	USD
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	99338000	USD
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	56196000	USD
CY2017	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	29443000	USD
CY2018	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	15526000	USD
CY2017	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9338000	USD
CY2019	us-gaap	Operating Expenses OperatingExpenses	115432000	USD
CY2018	us-gaap	Operating Expenses OperatingExpenses	71722000	USD
CY2017	us-gaap	Operating Expenses OperatingExpenses	38781000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-107432000	USD
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	-66722000	USD
CY2017	us-gaap	Operating Income Loss OperatingIncomeLoss	-28781000	USD
CY2019	us-gaap	Interest Expense InterestExpense	1041000	USD
CY2018	us-gaap	Interest Expense InterestExpense	1652000	USD
CY2017	us-gaap	Interest Expense InterestExpense	1775000	USD
CY2019	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2018	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2017	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1366000	USD
CY2019	us-gaap	Interest Income Other InterestIncomeOther	10984000	USD
CY2018	us-gaap	Interest Income Other InterestIncomeOther	6685000	USD
CY2017	us-gaap	Interest Income Other InterestIncomeOther	1623000	USD
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1000	USD
CY2018	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-159000	USD
CY2017	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	229000	USD
CY2019	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	9944000	USD
CY2018	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	4874000	USD
CY2017	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1289000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-97488000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-61848000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-152000	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-192000	USD
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-97336000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-61656000	USD
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-30070000	USD
CY2019	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	561000	USD
CY2018	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	203000	USD
CY2017	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	-426000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-96775000	USD
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-61453000	USD
CY2017	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-30496000	USD
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.60
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.50
CY2018	anab	Stock Issued During Period Value Due To Warrants Exercised StockIssuedDuringPeriodValueDueToWarrantsExercised	76000	USD
CY2018	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	9961000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	203000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-61656000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	486365000	USD
CY2019	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3007000	USD
CY2017	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.52
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	27059000	shares
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	24673000	shares
CY2017	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	19782000	shares
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	-38248000	USD
CY2017	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	292537000	USD
CY2017	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	4228000	USD
CY2017	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	979000	USD
CY2017	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	77516000	USD
CY2017	anab	Stock Issued During Period Value Due To Warrants Exercised StockIssuedDuringPeriodValueDueToWarrantsExercised	536000	USD
CY2017	anab	Adjustments To Additional Paid In Capital Warrants Reclassified AdjustmentsToAdditionalPaidInCapitalWarrantsReclassified	4607000	USD
CY2017	anab	Adjustmentsto Additional Paidin Capital Forfeiture Rate Adjustment AdjustmentstoAdditionalPaidinCapitalForfeitureRateAdjustment	0	USD
CY2017	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	4378000	USD
CY2017	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-426000	USD
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-30070000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	307581000	USD
CY2018	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	227476000	USD
CY2018	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	145000	USD
CY2018	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2869000	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	12411000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	561000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-97336000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	405008000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-97336000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-61656000	USD
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-30070000	USD
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	514000	USD
CY2018	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	315000	USD
CY2017	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	183000	USD
CY2019	anab	Sharebased Compensation And Issuance Of Stock And Warrants For Services Or Claims SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims	12411000	USD
CY2018	anab	Sharebased Compensation And Issuance Of Stock And Warrants For Services Or Claims SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims	9961000	USD
CY2017	anab	Sharebased Compensation And Issuance Of Stock And Warrants For Services Or Claims SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims	4378000	USD
CY2019	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2018	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2017	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1366000	USD
CY2019	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	2633000	USD
CY2018	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	1233000	USD
CY2017	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-11000	USD
CY2019	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-676000	USD
CY2018	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-646000	USD
CY2017	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-619000	USD
CY2019	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	0	USD
CY2018	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	139000	USD
CY2017	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	0	USD
CY2019	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	0	USD
CY2018	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	0	USD
CY2017	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	-1225000	USD
CY2019	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	-174000	USD
CY2018	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	-1427000	USD
CY2017	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	-2517000	USD
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2178000	USD
CY2018	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	5188000	USD
CY2017	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1885000	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	14499000	USD
CY2018	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	7083000	USD
CY2017	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	2218000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-69517000	USD
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-48506000	USD
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-19438000	USD
CY2019	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	251815000	USD
CY2018	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	347537000	USD
CY2017	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	290905000	USD
CY2019	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	384051000	USD
CY2018	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	206149000	USD
CY2017	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	48137000	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	805000	USD
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1063000	USD
CY2017	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	290000	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	131431000	USD
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-142451000	USD
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-243058000	USD
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2018	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	227476000	USD
CY2018	us-gaap	Interest Paid Net InterestPaidNet	1043000	USD
CY2017	us-gaap	Interest Paid Net InterestPaidNet	1089000	USD
CY2019	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	41000	USD
CY2018	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	159000	USD
CY2017	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	292537000	USD
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3007000	USD
CY2018	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2869000	USD
CY2017	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	979000	USD
CY2019	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2018	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	76000	USD
CY2017	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	536000	USD
CY2019	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	7500000	USD
CY2017	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	191000	USD
CY2019	anab	Stock Issuance Costs Incurred During Noncash Transaction StockIssuanceCostsIncurredDuringNoncashTransaction	0	USD
CY2018	anab	Stock Issuance Costs Incurred During Noncash Transaction StockIssuanceCostsIncurredDuringNoncashTransaction	0	USD
CY2018	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	6875000	USD
CY2017	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	USD
CY2019	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
CY2018	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	182000	USD
CY2017	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1599000	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-4493000	USD
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	223364000	USD
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	292453000	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	57421000	USD
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	32407000	USD
CY2017	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	29957000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	113656000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	81249000	USD
CY2016Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	51292000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	171077000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	113656000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	81249000	USD
CY2019	us-gaap	Interest Paid Net InterestPaidNet	424000	USD
CY2017	anab	Stock Issuance Costs Incurred During Noncash Transaction StockIssuanceCostsIncurredDuringNoncashTransaction	37000	USD
CY2019	anab	Transfer Of Warrants To Equity TransferOfWarrantsToEquity	0	USD
CY2018	anab	Transfer Of Warrants To Equity TransferOfWarrantsToEquity	0	USD
CY2017	anab	Transfer Of Warrants To Equity TransferOfWarrantsToEquity	4607000	USD
CY2019	us-gaap	Nature Of Operations NatureOfOperations	Description of the Business <div style="line-height:120%;padding-top:8px;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">AnaptysBio, Inc. (“we,” “us,” “our,” or the “Company”) was incorporated in the state of Delaware in November 2005. We are a clinical stage biotechnology company developing first-in-class immunology therapeutic product candidates to patients. We are focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications. We develop our product candidates using our proprietary antibody discovery technology platform, which is based upon a breakthrough understanding of the natural process of antibody generation, known as somatic hypermutation, or SHM, and replicates this natural process of antibody generation </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">in vitro</span><span style="font-family:inherit;font-size:10pt;">. We currently generate revenue from milestones achieved under our collaborative research and development arrangements. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Since our inception, we have devoted our primary effort to raising capital and research and development activities. Our financial support has been provided primarily from the sale of our common and preferred stock, as well as through funds received under our collaborative research and development agreements. Going forward, as we continue our expansion, we may seek additional financing and/or strategic investments. However, there can be no assurance that any additional financing or strategic investments will be available to us on acceptable terms, if at all. If events or circumstances occur such that we do not obtain additional funding, we will most likely be required to reduce our plans and/or certain discretionary spending, which could have a material adverse effect on our ability to achieve our intended business objectives. Management believes its currently available resources will provide sufficient funds to enable the Company to meet its operating plans for at least the next twelve months. The accompanying consolidated financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern.</span></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Public Offerings and Related Transactions</span></div><div style="line-height:120%;padding-top:24px;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Initial Public Offering</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On January 31, 2017, we completed an initial public offering, or IPO, selling </span><span style="font-family:inherit;font-size:10pt;"><span>5,750,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares, which included the exercise of the underwriters’ option to purchase an additional </span><span style="font-family:inherit;font-size:10pt;"><span>750,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock, at </span><span style="font-family:inherit;font-size:10pt;"><span>$15.00</span></span><span style="font-family:inherit;font-size:10pt;"> per share. Proceeds from our initial public offering net of underwriting discounts and commissions were </span><span style="font-family:inherit;font-size:10pt;"><span>$80.2 million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, each of the following occurred in connection with the completion of the IPO on January 31, 2017:</span></div><div style="line-height:120%;padding-left:42px;padding-top:8px;text-align:left;text-indent:0px;"><span style="padding-top:8px;text-align:left;font-family:inherit;font-size:10pt;padding-right:6px;">•</span><span style="font-family:inherit;font-size:10pt;"> the conversion of all outstanding shares of convertible preferred stock into </span><span style="font-family:inherit;font-size:10pt;"><span>11,520,698</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock; and</span></div><div style="line-height:120%;padding-left:42px;padding-top:8px;text-align:left;text-indent:0px;"><span style="padding-top:8px;text-align:left;font-family:inherit;font-size:10pt;padding-right:6px;">•</span><span style="font-family:inherit;font-size:10pt;"> the conversion of warrants to purchase </span><span style="font-family:inherit;font-size:10pt;"><span>377,195</span></span><span style="font-family:inherit;font-size:10pt;"> shares of convertible preferred stock into warrants to purchase </span><span style="font-family:inherit;font-size:10pt;"><span>377,195</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock and the resultant reclassification of the warrant liability to additional paid-in capital.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:33px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Follow-on Public Offerings </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On October 17, 2017, we completed an underwritten public offering selling </span><span style="font-family:inherit;font-size:10pt;"><span>3,000,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock. All shares were offered by us at a price to the public of </span><span style="font-family:inherit;font-size:10pt;"><span>$68.50</span></span><span style="font-family:inherit;font-size:10pt;"> per share. The aggregate net proceeds received by us from the offering were </span><span style="font-family:inherit;font-size:10pt;"><span>$194.7 million</span></span><span style="font-family:inherit;font-size:10pt;">, net of underwriting discounts and commissions. As part of the underwritten public offering, on November 14, 2017, the underwriters exercised an additional </span><span style="font-family:inherit;font-size:10pt;"><span>271,380</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock at a discounted price to the public of </span><span style="font-family:inherit;font-size:10pt;"><span>$68.50</span></span><span style="font-family:inherit;font-size:10pt;"> per share for aggregate net proceeds of </span><span style="font-family:inherit;font-size:10pt;"><span>$17.6 million</span></span><span style="font-family:inherit;font-size:10pt;">, net of underwriting discounts and commissions.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On September 28, 2018, we completed an underwritten public offering of </span><span style="font-family:inherit;font-size:10pt;"><span>2,530,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock, which included the exercise of the underwriters’ option to purchase an additional </span><span style="font-family:inherit;font-size:10pt;"><span>330,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock. All shares were offered by us at a price to the public of </span><span style="font-family:inherit;font-size:10pt;"><span>$94.46</span></span><span style="font-family:inherit;font-size:10pt;"> per share. The aggregate net proceeds received by us from the offering were </span><span style="font-family:inherit;font-size:10pt;"><span>$227.5 million</span></span><span style="font-family:inherit;font-size:10pt;">, net of underwriting discounts and commissions.</span></div>
CY2017Q4	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	3000000	shares
CY2017Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	68.50
CY2017Q4	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	194700000	USD
CY2018Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	2530000	shares
CY2018Q3	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	94.46
CY2018Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	227500000	USD
CY2019	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2019	us-gaap	Use Of Estimates UseOfEstimates	<div style="line-height:120%;padding-top:24px;text-align:left;padding-left:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The preparation of the accompanying consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. We base our estimates and assumptions on historical experience when available and on various factors that we believe to be reasonable under the circumstances. We evaluate our estimates and assumptions on an ongoing basis. Our actual results could differ from these estimates under different assumptions or conditions.</span></div>
CY2019Q4	us-gaap	Restricted Cash RestrictedCash	60000	USD
CY2019	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="line-height:120%;padding-top:26px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentration of Credit Risk</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject us to a concentration of credit risk consist of cash and cash equivalents and certain investments in money market funds, certificates of deposit, agency securities, commercial obligations and U.S. treasury securities. Bank deposits are diversified between </span><span style="font-family:inherit;font-size:10pt;"><span>three</span></span><span style="font-family:inherit;font-size:10pt;"> financial institutions and these deposits may exceed insured limits. We are exposed to credit risk in the event of default by the financial institutions holding our cash and cash equivalents and issuers of investments that are recorded on our consolidated balance sheets. We mitigate our risk by investing in high-grade instruments and limiting the concentration in any one issuer, which limits our exposure.</span></div>
CY2019	anab	Number Of Financial Institutions Utilized For Diversification Of Funds NumberOfFinancialInstitutionsUtilizedForDiversificationOfFunds	3	bank
CY2019	us-gaap	Property Plant And Equipment Impairment PropertyPlantAndEquipmentImpairment	<div style="line-height:120%;padding-top:24px;text-align:left;padding-left:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Long Lived Assets </span></div>Long-lived assets, consisting of property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable based on undiscounted cash flows. If long-lived assets are impaired, an impairment loss is recognized and is measured as the amount by which the carrying value exceeds the estimated fair value of the assets.
CY2019	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	0	USD
CY2019Q4	anab	Income Tax Incentive Research And Development Revenue Threshold For Reimbursable Period IncomeTaxIncentiveResearchAndDevelopmentRevenueThresholdForReimbursablePeriod	20000000.0	AUD
CY2018Q4	anab	Accrued Research And Development Expenses Current AccruedResearchAndDevelopmentExpensesCurrent	5577000	USD
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	269000	USD
CY2018Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	321000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	11052000	USD
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2462000	shares
CY2018	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2451000	shares
CY2016	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2639000	shares
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	6297000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	5642000	USD
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4679000	USD
CY2018Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4197000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1618000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1445000	USD
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2152000	USD
CY2018Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2421000	USD
CY2019Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	435000	USD
CY2018Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	442000	USD
CY2019Q4	anab	Accrued Research And Development Expenses Current AccruedResearchAndDevelopmentExpensesCurrent	8196000	USD
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8761000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	256969000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	552000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	6000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	257515000	USD
CY2017Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	27255082	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3039880	shares
CY2019Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	5642223	shares
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2152455	shares
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	27.55
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1608917	shares
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	34.31
CY2019	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	333260	shares
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	9.02
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	388232	shares
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	56.98
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3039880	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	29.40
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y8M15D
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	10156000	USD
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1316137	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	22.73
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y9M7D
CY2019Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	8374000	USD
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3000000.0	USD
CY2019	anab	Sharebased Compensation And Issuance Of Stock And Warrants For Services Or Claims SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims	12411000	USD
CY2018	anab	Sharebased Compensation And Issuance Of Stock And Warrants For Services Or Claims SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims	9961000	USD
CY2017	anab	Sharebased Compensation And Issuance Of Stock And Warrants For Services Or Claims SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims	4378000	USD
CY2019Q4	anab	Employee And Nonemployee Service Sharebased Compensation Nonvested Awards Compensation Not Yet Recognized Stock Options EmployeeAndNonemployeeServiceSharebasedCompensationNonvestedAwardsCompensationNotYetRecognizedStockOptions	34800000	USD
CY2019	anab	Research And Development Tax Incentive Credit Received During Period ResearchAndDevelopmentTaxIncentiveCreditReceivedDuringPeriod	200000	USD
CY2018	anab	Research And Development Tax Incentive Credit Received During Period ResearchAndDevelopmentTaxIncentiveCreditReceivedDuringPeriod	1500000	USD
CY2019Q4	anab	Research And Development Tax Incentive Credit Receivable Current ResearchAndDevelopmentTaxIncentiveCreditReceivableCurrent	0	USD
CY2019	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	0.50
CY2019	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.06
CY2019	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Amount DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount	6000	USD
CY2019	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	300000	USD
CY2018	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	0	USD
CY2019	anab	Lessee Operating Lease Number LesseeOperatingLeaseNumber	2	lease
CY2019Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P2Y
CY2019Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0859
CY2018	anab	Collaboration License Agreement Upfront Milestone And Royalty Expense CollaborationLicenseAgreementUpfrontMilestoneAndRoyaltyExpense	300000	USD
CY2017	anab	Collaboration License Agreement Upfront Milestone And Royalty Expense CollaborationLicenseAgreementUpfrontMilestoneAndRoyaltyExpense	500000	USD
CY2019	anab	Payments For Upfront Milestone And Royalty Payments PaymentsForUpfrontMilestoneAndRoyaltyPayments	100000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-97488000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-61848000	USD
CY2018	anab	Payments For Upfront Milestone And Royalty Payments PaymentsForUpfrontMilestoneAndRoyaltyPayments	200000	USD
CY2018	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	700000	USD
CY2017	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	500000	USD
CY2018Q4	us-gaap	Deferred Rent Credit DeferredRentCredit	200000	USD
CY2017	anab	Payments For Upfront Milestone And Royalty Payments PaymentsForUpfrontMilestoneAndRoyaltyPayments	600000	USD
CY2019Q4	us-gaap	Other Commitment Due In Next Twelve Months OtherCommitmentDueInNextTwelveMonths	200000	USD
CY2019	anab	Collaboration License Agreement Obligation Payable Period CollaborationLicenseAgreementObligationPayablePeriod	P10Y
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-97187000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-61193000	USD
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-27494000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-301000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-655000	USD
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-2576000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1402000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	871000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	654000	USD
CY2019	us-gaap	Operating Lease Cost OperatingLeaseCost	879000	USD
CY2019	us-gaap	Operating Lease Payments OperatingLeasePayments	937000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	969000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	676000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	0	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	0	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	0	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	0	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1645000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	120000	USD
CY2019Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1525000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	937000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	969000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	726000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	0	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	0	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	0	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	2632000	USD
CY2019	anab	Collaboration License Agreement Maximum Term CollaborationLicenseAgreementMaximumTerm	P19Y
CY2019	anab	Collaboration License Agreement Upfront Milestone And Royalty Expense CollaborationLicenseAgreementUpfrontMilestoneAndRoyaltyExpense	500000	USD
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-30070000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	55722000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	35499000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	14244000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	9190000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	4866000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	2948000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	74832000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	47637000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	349000	USD
CY2018Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	49000	USD
CY2019Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	349000	USD
CY2018Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	49000	USD
CY2019Q4	anab	Deferred Tax Assets Net Before Valuation Allowance DeferredTaxAssetsNetBeforeValuationAllowance	74483000	USD
CY2018Q4	anab	Deferred Tax Assets Net Before Valuation Allowance DeferredTaxAssetsNetBeforeValuationAllowance	47588000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	74483000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	47588000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2018Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2019	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-20473000	USD
CY2018	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-12988000	USD
CY2017	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-10223000	USD
CY2019	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-377000	USD
CY2018	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-166000	USD
CY2017	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-787000	USD
CY2019	us-gaap	Income Tax Reconciliation Tax Exempt Income IncomeTaxReconciliationTaxExemptIncome	-34000	USD
CY2018	us-gaap	Income Tax Reconciliation Tax Exempt Income IncomeTaxReconciliationTaxExemptIncome	-17000	USD
CY2017	us-gaap	Income Tax Reconciliation Tax Exempt Income IncomeTaxReconciliationTaxExemptIncome	-13000	USD
CY2019	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-1122000	USD
CY2018	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-6693000	USD
CY2017	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-739000	USD
CY2019	anab	Effective Income Tax Rate Reconciliation Change In Fair Value Of Preferred Stock Warrant Liabilities EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPreferredStockWarrantLiabilities	0	USD
CY2018	anab	Effective Income Tax Rate Reconciliation Change In Fair Value Of Preferred Stock Warrant Liabilities EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPreferredStockWarrantLiabilities	0	USD
CY2017	anab	Effective Income Tax Rate Reconciliation Change In Fair Value Of Preferred Stock Warrant Liabilities EffectiveIncomeTaxRateReconciliationChangeInFairValueOfPreferredStockWarrantLiabilities	464000	USD
CY2019	us-gaap	Income Tax Reconciliation Nondeductible Expense Research And Development IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment	0	USD
CY2018	us-gaap	Income Tax Reconciliation Nondeductible Expense Research And Development IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment	63000	USD
CY2017	us-gaap	Income Tax Reconciliation Nondeductible Expense Research And Development IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment	679000	USD
CY2019	anab	Effective Income Tax Rate Reconciliation Alternative Minimum Tax EffectiveIncomeTaxRateReconciliationAlternativeMinimumTax	0	USD
CY2018	anab	Effective Income Tax Rate Reconciliation Alternative Minimum Tax EffectiveIncomeTaxRateReconciliationAlternativeMinimumTax	139000	USD
CY2017	anab	Effective Income Tax Rate Reconciliation Alternative Minimum Tax EffectiveIncomeTaxRateReconciliationAlternativeMinimumTax	0	USD
CY2019	us-gaap	Income Tax Reconciliation Tax Settlements IncomeTaxReconciliationTaxSettlements	-661000	USD
CY2018	us-gaap	Income Tax Reconciliation Tax Settlements IncomeTaxReconciliationTaxSettlements	60000	USD
CY2017	us-gaap	Income Tax Reconciliation Tax Settlements IncomeTaxReconciliationTaxSettlements	11000	USD
CY2019	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-53000	USD
CY2018	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	155000	USD
CY2017	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	297000	USD
CY2019	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	0	USD
CY2018	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	0	USD
CY2017	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	7595000	USD
CY2019	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	4405000	USD
CY2018	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	4393000	USD
CY2017	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	1554000	USD
CY2019	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	26905000	USD
CY2018	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	23892000	USD
CY2017	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	4244000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-152000	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-192000	USD
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	1100000	USD
CY2019	anab	Effective Income Tax Rate Reconciliation Nondeductible Expense Sharebased Compensation Cost Disqualifying Dispositions Of Incentive Stock Options EffectiveIncomeTaxRateReconciliationNondeductibleExpenseSharebasedCompensationCostDisqualifyingDispositionsOfIncentiveStockOptions	300000	USD
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	4900000	USD
CY2018	anab	Effective Income Tax Rate Reconciliation Nondeductible Expense Sharebased Compensation Cost Disqualifying Dispositions Of Incentive Stock Options EffectiveIncomeTaxRateReconciliationNondeductibleExpenseSharebasedCompensationCostDisqualifyingDispositionsOfIncentiveStockOptions	2200000	USD
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	400000	USD
CY2017	anab	Effective Income Tax Rate Reconciliation Nondeductible Expense Sharebased Compensation Cost Disqualifying Dispositions Of Incentive Stock Options EffectiveIncomeTaxRateReconciliationNondeductibleExpenseSharebasedCompensationCostDisqualifyingDispositionsOfIncentiveStockOptions	700000	USD
CY2018	us-gaap	Tax Cuts And Jobs Act Of2017 Change In Tax Rate Deferred Tax Asset Income Tax Expense TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxAssetIncomeTaxExpense	7600000	USD
CY2018	us-gaap	Tax Cuts And Jobs Act Of2017 Change In Tax Rate Deferred Tax Asset Income Tax Expense TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxAssetIncomeTaxExpense	7600000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	0	USD
CY2018Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-19663000	USD
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	-66722000	USD
CY2018Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-15086000	USD
CY2018Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-13618000	USD
CY2018Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-15958000	USD
CY2018Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-16994000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1812000	USD
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	591000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	168000	USD
CY2018	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	9000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1166000	USD
CY2018	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1212000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3146000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1812000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	USD
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-24772000	USD
CY2019Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-26657000	USD
CY2019Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-33745000	USD
CY2019Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-22258000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-107432000	USD
CY2019Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-22078000	USD
CY2019Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-23962000	USD
CY2019Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-31033000	USD
CY2019Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-20263000	USD
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-97336000	USD
CY2019Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.82
CY2019Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.89
CY2019Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.15
CY2019Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.75
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.60
CY2019Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.82
CY2019Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.89
CY2019Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.15
CY2019Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.75
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.60
CY2018Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-15757000	USD
CY2018Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-14415000	USD
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-16887000	USD
CY2018	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-61656000	USD
CY2018Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.63
CY2018Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.57
CY2018Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.66
CY2018Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.64
CY2018	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.50
CY2018Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.63
CY2018Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.57
CY2018Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.66
CY2018Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.64
CY2018	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.50

Files In Submission

Name	View Source	Status
0001370053-20-000009-index-headers.html	Edgar Link	pending
0001370053-20-000009-index.html	Edgar Link	pending
0001370053-20-000009.txt	Edgar Link	pending
0001370053-20-000009-xbrl.zip	Edgar Link	pending
anab-12311910k.htm	Edgar Link	pending
anab-12311910k_htm.xml	Edgar Link	completed
anab-123119x10kxexx311.htm	Edgar Link	pending
anab-123119x10kxexx312.htm	Edgar Link	pending
anab-123119x10kxexx321.htm	Edgar Link	pending
anab-123119x10kxexx322.htm	Edgar Link	pending
anab-123119xexx211.htm	Edgar Link	pending
anab-123119xexx231.htm	Edgar Link	pending
anab-20191231.xsd	Edgar Link	pending
anab-20191231_cal.xml	Edgar Link	unprocessable
anab-20191231_def.xml	Edgar Link	unprocessable
anab-20191231_lab.xml	Edgar Link	unprocessable
anab-20191231_pre.xml	Edgar Link	unprocessable
anabtotalreturngraph.jpg	Edgar Link	pending
anaptys-10xkfy2019xexh.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
pipelinebarchart.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ANAB
ANAPTYSBIO, INC Stock $anab

2020 Q1 Form 10-K Financial Statement

#000137005320000009 Filed on March 02, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ANAB ANAPTYSBIO, INC Stock $anab

2020 Q1 Form 10-K Financial Statement

#000137005320000009 Filed on March 02, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ANAB
ANAPTYSBIO, INC Stock $anab